Targeted Therapeutic Nanoparticles: An Immense Promise to Fight against Cancer

Table 4

Some examples of PEG-modified PLGA NPs with preparation methods, targeting ligands, size, zeta potential, and applications.

Polymer	Targeting ligand	Conjugation method	Average size; (nm)	Zeta potential; (mV)	Applications	Reference
PEGylated PLGA	A10 aptamer	Covalent conjugation	188	N/A	Targeting human xenograft prostate cancer in mice	[93]
PLGA-PEG	—	Covalent conjugation	170	N/A	NPs encapsulating endostar slowed growth of tumor xenografts	[94]
PEGylated PLGA	cLABL	Covalent conjugation	244	−23.3	Targeting the vascular endothelium with upregulated ICAM-1	[95]
50/50 PLGA and Palmitate-Avidin	Biotinylated PEG, and horseradish peroxidase	Streptavidin-biotin noncovalent binding	170	−11.3	Diffusion of PEGylated particles cervical mucus was 3–10x higher than unmodified PLGA	[96]
PLGA-PEG	—	Covalent conjugation	148	1.84	Sustained release of 9-nitrocamptothecin	[97]
PLGA-PEG		Covalent conjugation	65–100	N/A	Sustained release of adriamycin	[98]
PLA-PEG		Covalent conjugation	952	Neutral	Reduced opsonization of NPs	[99]
PLGA and PEG-distearyl; Phosphoethanolamine (PEGPE)		Coemulsification	20–40	−19.2	Higher Doxorubicin encapsulation efficiency, slower release rate, and rapid cellular uptake	[100]
PLGA-mPEG		Covalent conjugation	N/A	N/A	Reduction in protein adsorption on the surface films of PLGA-PEG (750 and 2000) compared to adsorption onto PLGA only	[101]
PLGA	PEG/poloxamer 407	Coincorporation or surface adsorption	189–225	(−16.1)–(−20.3)	Increased blood circulation half-life of NPs	[102]
PLGA-PEG di-block (15% PEG with 5 kDa)		Covalent conjugation	114	−2.8	Higher cellular uptake of formulations containing 15% of PEG compared to 5% and 10% PEG-PLGA formulations	[103]